ClearPoint Neuro (NASDAQ:CLPT) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen cut shares of ClearPoint Neuro (NASDAQ:CLPT) from a hold rating to a sell rating in a research note published on Thursday morning.

Several other brokerages have also recently commented on CLPT. B. Riley lifted their price target on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th. Stifel Nicolaus increased their price objective on shares of ClearPoint Neuro from $19.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, April 1st.

ClearPoint Neuro Stock Down 0.7%

CLPT stock opened at $12.08 on Thursday. ClearPoint Neuro has a twelve month low of $5.11 and a twelve month high of $19.22. The company has a market cap of $338.11 million, a P/E ratio of -17.51 and a beta of 1.03. The business has a fifty day moving average of $12.83 and a 200-day moving average of $14.21.

ClearPoint Neuro (NASDAQ:CLPT) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.07). The firm had revenue of $8.49 million during the quarter, compared to analyst estimates of $8.21 million. ClearPoint Neuro had a negative return on equity of 62.10% and a negative net margin of 59.64%. As a group, equities research analysts anticipate that ClearPoint Neuro will post -0.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ClearPoint Neuro

A number of institutional investors have recently made changes to their positions in the stock. R Squared Ltd bought a new position in ClearPoint Neuro during the fourth quarter worth about $32,000. AlphaQuest LLC bought a new stake in shares of ClearPoint Neuro in the 4th quarter valued at about $80,000. Deutsche Bank AG bought a new stake in shares of ClearPoint Neuro in the 1st quarter valued at about $63,000. Barclays PLC raised its position in shares of ClearPoint Neuro by 24.3% in the 3rd quarter. Barclays PLC now owns 5,674 shares of the company’s stock valued at $64,000 after acquiring an additional 1,109 shares during the period. Finally, Tower Research Capital LLC TRC acquired a new stake in shares of ClearPoint Neuro in the 4th quarter valued at approximately $93,000. 30.08% of the stock is owned by institutional investors and hedge funds.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.